CA2 Destabilizing Domains for Tunable Therapeutic Protein Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene and cell therapies lack the ability to titrate the timing or levels of target protein induction, making it difficult to safely and effectively express proteins with narrow therapeutic windows or those requiring transient expression.
Innovation Solution
Utilizing destabilizing domains (DDs) derived from human carbonic anhydrase 2 (CA2) that stabilize or destabilize a payload protein based on the presence or absence of a small molecule ligand, allowing for tunable and temporal control of protein expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If destabilizing domains are used to enable tunable protein expression, then protein stability control is improved, but system complexity increases
Solution Approach 1:
The system divides the control mechanism into separate functional modules: destabilizing domains (DDs) that confer instability, small molecule ligands that bind to DDs to stabilize them, and payload proteins that require controlled expression. This segmentation allows each component to be optimized independently while providing modular tunability of protein expression through ligand-induced stabilization of specific DD-fused proteins.
2Reliability
If protein expression is tightly regulated for narrow therapeutic windows, then safety is improved, but ease of operation deteriorates
Solution Approach 1:
Small molecule ligands serve as intermediaries between the operator and the protein expression system. By adding or removing these ligands, users can precisely control the stability and expression levels of target proteins without complex genetic circuits or multiple regulatory elements. The ligand acts as a simple, reversible switch that provides tight control for proteins with narrow therapeutic windows.
3Reliability
If transient protein expression is required, then therapeutic efficacy is improved, but duration of action deteriorates
Solution Approach 1:
The system enables transient protein expression through periodic or pulsed addition of stabilizing ligands. By controlling the timing and duration of ligand exposure, the system can induce protein expression only during specific time windows when therapeutic effect is needed, then allow rapid degradation when ligand is removed. This periodic control mechanism achieves high therapeutic efficacy with minimal duration of action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables safe and effective regulation of protein expression and function in cell and gene therapies, expanding the range of therapeutic applications by providing tunable and transient protein delivery.
Implementation Method 1
when a specific small molecule DD-binding ligand binds to the DD, the attached protein of interest is stabilized
Data Source
AI summary
The present disclosure provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.